A New Look at Intravenous Platelet Inhibitors in the Cath Lab

Welcoming Remarks

Srihari S. Naidu, MD, FSCAI

ACS PCI (Case #1) With Panel Discussion: To Pre-load or Not to Pre-load, That Is the Question

Deepak L. Bhatt, M.D., M.P.H., MSCAI

IV Platelet Inhibition During High-risk PCI: Which Patients Benefit the Most?

Michelle O'Donoghue, MD, MPH

IV Platelet Inhibition for Bridging: A When-To and How-To Guide

George D. Dangas, M.D., Ph.D., MSCAI

IV Platelet Inhibition in Cardiogenic Shock: Should We Be Using in All Shock Patients?

Babar B Basir, DO, FSCAI

Complex PCI (Case #2) With Panel Discussion: PCI in Complex Stable CAD

Suzanne J. Baron, M.D., FSCAI

Panel Discussion

Automation, AI, and Robotics—Leading Innovation in the Cath Lab

Welcoming Remarks

Farouc A. Jaffer, M.D., Ph.D., FSCAI

Angio-Derived FFR: Changing the Physiology Paradigm

Ziad A. Ali, M.D., Ph.D.

Advancing PCI Through Robotic Automation

Kathleen Kearney, M.D., FSCAI

CTO Intervention With Real-Time CT Fusion Guidance

Emmanouil S. Brilakis, MD, PhD, FSCAI

Future of Telemedicine and Remote PCI

Ryan D. Madder, M.D., FSCAI

Panel Discussion

Concluding Remarks

Ziad A. Ali, M.D., Ph.D.

Defining HBR: Leading the Way in High Bleeding Risk Patients

Introductory Remarks

Ashok Seth, FRCP,, MSCAI

Live Case: Negotiating in HBR Patient From APOLLO Hospital, Visakhapatnam, India

Dibya Kumar Baruah, M.D.

Defining High Bleeding Risk

Murugesh Shantaveeraya Hiremath, M.D.

Discussion

Acute MI With Left Main, Multi Vessel, and Anemia

Balbir Singh, MD

Discussion

Old Surgery, New Question?

Prakash Chandra Mondal, MD

Discussion

Concluding Remarks

Mathew K. Samuel, M.D., FSCAI

Emerging Technologies in cPCI

Welcome and Introductions

Jasvindar (Jas) Singh, MD, FSCAI

Low & Ultra-Low Contrast PCI for the Patient With CKD–—What Every IC Should Know

Jasvindar (Jas) Singh, MD, FSCAI

Eliminating “Renalism”: A Review of Clinical Access, Procedural Risks, and Optimizing Care for Patients With CKD

Ziad A. Ali, M.D., Ph.D.

How to Perform Low & Ultra-Low Contrast PCI

Ashish Pershad, M.D., FSCAI

The Value of a Cardio-Renal Program—What We Did and How It’s Working

Amir Kaki, M.D., FSCAI

Putting It All Together, Case Example

Jasvindar (Jas) Singh, MD, FSCAI

Panel Discussion

Insights and Implications on Reduction of Ischemic Events With Eicosapentaenoic Acid

Welcome and Opening Remarks

C. Michael Gibson, M.D., MSCAI

Cardiovascular Outcomes Trials of Omega-3 Fatty Acids in ASCVD

Deepak L. Bhatt, M.D., M.P.H., MSCAI

Mechanistic Clues to Omega-3 Fatty Acid CV Benefits: Focus on Coronary Plaque Regression and Stabilization

Matthew J. Budoff, M.D.

Panel Discussion

Intravascular Lithotripsy for Treatment of Complex Coronary Lesions

Welcoming Remarks

Dean J. Kereiakes, M.D., MSCAI

IVL Coronary Clinical Trials

Dean J. Kereiakes, M.D., MSCAI

Expanded Use and Post-Market Studies

Jonathan Michael Hill, M.D.

IVL Complex Coronary Case Examples

Robert F. Riley, M.D., FSCAI

Panel Discussion

Concluding Remarks

Robert F. Riley, M.D., FSCAI

Left Main & Coronary Bifurcation Summit (CBS)—SCAI Bifurcation Club Partnership Session

Introductory Remarks

Yaling Han, M.D.

Keynote: Comparing PCI and CABG in Left Main Disease

Gregg W. Stone, M.D.

Discussion

Live Case from Nanjing First Hospital, Nanjing Medical University

Shao-Liang Chen Sr., M.D., Ph.D., Junjie Zhang, M.D., FSCAI, Tao Pan

Concluding Remarks

Cindy L. Grines, M.D., MSCAI, Yaling Han, M.D.

Looking at the Acute Decompensated Heart Failure (ADHF) Patient in Cardiogenic Shock

Welcoming Remarks

Navin K. Kapur, M.D., FSCAI

Acutely Decompensated Heart Failure (ADHF) and Cardiogenic Shock: Fundamental Principles

Navin K. Kapur, M.D., FSCAI

Mechanistic Rationale for Acute MCS Device Selection in Advanced Heart Failure

Jennifer Cowger, MD

Clinical Data Evaluating the Use of Acute MCS in ADHF

A. Reshad Reshad Garan, MD

Panel Discussion

Shock Algorithms Tailored to the Patient With Advanced Heart Failure

Haval Chweich

Design and Rationale for the Alt-Shock Trial

Nuccia Morici

Case Presentation

Jaime Hernandez-Montfort, MD MPH MSc

Panel Discussion

Concluding Remarks

Jerry D. Estep, M.D.

Managing Cardiogenic Shock: A Case-Based Approach

Introduction

Alexander G. Truesdell, M.D., FSCAI

Acute MI Cardiogenic Shock—Case Presentation

Katherine Kunkel, M.D., FSCAI

Shock Protocols, Shock Teams, Shock Centers, and Shock Networks

Behnam N. Tehrani, M.D.

RV Failure, Escalation, and Futility

A. Reshad Reshad Garan, MD

Cardiac Intensive Care Unit Shock Management: Best Practices

Timothy D. Smith, M.D., FSCAI

Acute MI Cardiogenic Shock—Case Conclusion

Katherine Kunkel, M.D., FSCAI

Discussion

Concluding Remarks

Michele Voeltz, M.D.

Modern Day Management of Aortic Stenosis in Younger Patients

Welcome and Introductions

James B. Hermiller, M.D., MSCAI, Mark J. Russo, M.D., David A. Wood, M.D., FSCAI

Anatomical Considerations

James B. Hermiller, M.D., MSCAI

Social Factors and Patient Preference and Key Takeaways from Guidelines and the Heart Team Approach

Megan Coylewright, M.D., FSCAI

How to Use Echo in Long Term Monitoring of Valve Function?

Amr E. Abbas, M.D., FSCAI

SAVR or TAVR First? A Case-Based Discussion

Suzanne J. Baron, M.D., FSCAI

Panel Discussion

Planning for Success of Complex Interventions in the Cath Labs of Today and Tomorrow

Welcome and Introductions

Adhir R. Shroff, MD, FSCAI

Case: Complex Coronary Atherectomy and Same Day Discharge

Megan Toole, MD

Discuss SCAI Position Statement on Performing PCI in Ambulatory Surgery Centers

Deepali Nivas Tukaye, M.B.B.S., FSCAI

Lessons Learned: Complex Vascular Procedures in OBLs

Jeffrey G. Carr, M.D., FSCAI

DEBATE: Complex Coronary Interventions in ASCs: Can It Be Done Safely?

Georges Y. Nseir, M.D.

DEBATE: Complex Coronary Interventions and ASCs: Not Ready for Primetime, Yet

Arasi Maran, M.D., FSCAI

Panel Discussion

Polyvascular Disease: What Is Optimal Medical Therapy Following Peripheral Revascularization?

Welcoming Remarks

Ehrin J. Armstrong, M.D.

How Do We Identify Patients With Polyvascular Disease, and What Are the Outcomes of Polyvascular Disease?

Ehrin J. Armstrong, M.D.

Antithrombotic Agents for Patients With Polyvascular Disease: Before and After Peripheral Vascular Intervention

Marc P. Bonaca, MD, MPH

What Is the Role of SGLT2 and PCSK9 Inhibitors for Patients With Polyvascular Disease?

William Schuyler Jones, M.D.

Treatment of Carotid, Coronary, and Peripheral Artery Disease in a Single Patient: How to Manage?

Herb D. Aronow, MD, MPH, FSCAI

Panel Discussion

Protected PCI: Diagnosis and Treatment of High-Risk and Complex Coronary Disease for Superior Long-Term Outcomes

Welcoming Remarks

Duane S. Pinto, M.D., M.P.H.

“I really should have used support.” A Case-Based Approach to Patient Identification

Duane S. Pinto, M.D., M.P.H., Laurette Mbuntum, MD

Patient Identification: Appropriate Patient Selection

Rajan A. Patel, M.D., FSCAI

Efficacy of Extensive Revascularization at Index PCI With Impella Support

Ehtisham Mahmud, M.D., MSCAI

Skills and Tools Required for Complete and Safe Revascularization

Alejandro Lemor, M.D., FSCAI

Protect IV: New Data Supporting Complete and Supported Revascularization

Gregg W. Stone, M.D.

2021 Scientific Sessions

Satellite Sessions